Enarodustat vs Molidustat

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Chronic Kidney Disease

Shared mechanism: HIF prolyl hydroxylase (HIF-PH1/2/3) · full Chronic Kidney Disease pipeline

Enarodustat

Marketed by Shionogi and partners

Phase 3 in Chronic Kidney Diseasesmall molecule
Partial signal

NCT04027517 · Phase 3 · completed

The trial was randomized and actively controlled with 172 participants, but it was open-label and used hemoglobin, a laboratory surrogate, as its primary endpoint. Because no primary endpoint results or statistical comparison are available, the study provides limited evidence rather than demonstrating a positive or negative treatment effect.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: June 2027 · NCT07079579 (registry estimate)

Reported efficacy

Difference in mean Hb concentration levels from baseline at weeks 7-9 (Baseline and week 7-9): Mean Hb change from baseline averaged over Weeks 7-9: enarodustat +15.99 g/L (SD 9.46) vs placebo +0.14 g/L (SD 8.08); P<0.001 (met)

Result source: NCT06016036

Molidustat

Marketed by Bayer

Phase 3 in Chronic Kidney Diseasesmall molecule
Partial signal

NCT03543657 · Phase 3 · completed

The trial randomized 229 participants to molidustat or darbepoetin alfa with matching placebos and quadruple blinding. Its primary endpoints were hemoglobin measures, which are laboratory surrogate outcomes. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Reported efficacy

The mean Hb level during the evaluation period (From week 33 to 36); The change in mean Hb level during the evaluation period from baseline (Baseline and week 33 to 36): Mean Hb during evaluation period (weeks 33-36): molidustat 10.63 g/dL (95% CI 10.42-10.84) vs darbepoetin alfa 10.77 g/dL (95% CI 10.59-10.95); LS mean difference -0.13 g/dL (95% CI -0.46 to 0.19); noninferiority (margin 1.0 g/dL) established (met)

Result source: NCT03543657

Results for Chronic Kidney Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointEnarodustatMolidustat
Kidney composite outcome—Not posted · NCT04027517—Not posted · NCT03350347
UACR, % change—Not posted · NCT04027517—Not posted · NCT03350347
eGFR slope—Not posted · NCT04027517—Not posted · NCT03350347
Haemoglobin, change—Not posted · NCT04027517—Not posted · NCT03350347

Kidney composite outcome

Enarodustat
—Not posted · NCT04027517
Molidustat
—Not posted · NCT03350347

UACR, % change

Enarodustat
—Not posted · NCT04027517
Molidustat
—Not posted · NCT03350347

eGFR slope

Enarodustat
—Not posted · NCT04027517
Molidustat
—Not posted · NCT03350347

Haemoglobin, change

Enarodustat
—Not posted · NCT04027517
Molidustat
—Not posted · NCT03350347
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Enarodustat
평가기간 중 투여군간 차이 [95% 신뢰구간] -0.19 [-0.46, 0.08] (이 약 투여군 N=57 평가기간 중 Hb 농도 평균 10.65 g/dL, 다베포에틴 알파 투여군 N=67 10.83 g/dL; 베이스라인 10.73 vs 10.68 g/dL; 비열등성 마진 -1.0 g/dL) NCT04027517 · Phase 3 · design grade: moderate · reviewed ClinicalTrials.gov result
Mean Hb change from baseline averaged over Weeks 7-9: enarodustat +15.99 g/L (SD 9.46) vs placebo +0.14 g/L (SD 8.08); P<0.001 NCT06016036 · Phase 3 · design grade: strong · publication or press release

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Molidustat

Hgb Target Range 54.9%
responder rate · % of participants
No placebo or comparator arm
NCT03418168 · Phase 3 · sponsor-reported, not registry data

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Enarodustat's landscape · Molidustat's landscape